Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Aspirin for myocardial infarction. Clinical pharmacokinetic considerations.

× No keyword cloud information.

42 in total

1. Low-dose enteric-coated aspirin: a practical approach to continuous-release low-dose aspirin and presystemic acetylation of human platelet cyclooxygenase.

Authors: J A Jakubowski; M J Stampfer; R Vaillancourt; D Faigel; D Deykin
Journal: J Lab Clin Med Date: 1986-12

2. Rapidity and duration of platelet suppression by enteric-coated aspirin in healthy young men.

Authors: A H Jimenez; M E Stubbs; G H Tofler; K Winther; G H Williams; J E Muller
Journal: Am J Cardiol Date: 1992-01-15 Impact factor: 2.778

3. Pre-hospital opiate and aspirin administration in patients with suspected myocardial infarction.

Authors: H R Wyllie; F G Dunn
Journal: BMJ Date: 1994-03-19

Review 4. Is there an optimal dose and formulation of aspirin to prevent arterial thrombo-embolism in man?

Authors: F Bochner; J Lloyd
Journal: Clin Sci (Lond) Date: 1986-12 Impact factor: 6.124

5. Effects of early intervention with low-dose aspirin (100 mg) on infarct size, reinfarction and mortality in anterior wall acute myocardial infarction.

Authors: F W Verheugt; A van der Laarse; A J Funke-Küpper; L G Sterkman; T W Galema; J P Roos
Journal: Am J Cardiol Date: 1990-08-01 Impact factor: 2.778

6. Absorption kinetics of aspirin in man following oral administration of an aqueous solution.

Authors: M Rowland; S Riegelman; P A Harris; S D Sholkoff
Journal: J Pharm Sci Date: 1972-03 Impact factor: 3.534

7. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects.

Authors: P Patrignani; P Filabozzi; C Patrono
Journal: J Clin Invest Date: 1982-06 Impact factor: 14.808

8. Measurement of aspirin concentrations in portal and systemic blood in pigs: effect on platelet aggregation, thromboxane and prostacyclin production.

Authors: F Bochner; D M Siebert; S E Rodgers; G H McIntosh; M J James; J V Lloyd
Journal: Thromb Haemost Date: 1989-04-25 Impact factor: 5.249

Aspirin for myocardial infarction. Clinical pharmacokinetic considerations.

1. Low-dose enteric-coated aspirin: a practical approach to continuous-release low-dose aspirin and presystemic acetylation of human platelet cyclooxygenase.

2. Rapidity and duration of platelet suppression by enteric-coated aspirin in healthy young men.

3. Pre-hospital opiate and aspirin administration in patients with suspected myocardial infarction.

Review 4. Is there an optimal dose and formulation of aspirin to prevent arterial thrombo-embolism in man?

5. Effects of early intervention with low-dose aspirin (100 mg) on infarct size, reinfarction and mortality in anterior wall acute myocardial infarction.

6. Absorption kinetics of aspirin in man following oral administration of an aqueous solution.

7. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects.

8. Measurement of aspirin concentrations in portal and systemic blood in pigs: effect on platelet aggregation, thromboxane and prostacyclin production.

9. Aspirin does not improve early arterial patency after streptokinase treatment for acute myocardial infarction.

10. Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin.

1. Bioavailability prediction based on molecular structure for a diverse series of drugs.

2. Morphine interaction with prasugrel: a double-blind, cross-over trial in healthy volunteers.